http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111643684-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-14 |
| filingDate | 2020-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111643684-B |
| titleOfInvention | Gadolinium-based magnetic resonance imaging contrast agent with tumor targeting and preparation method thereof |
| abstract | The invention discloses a preparation method of a gadolinium-based magnetic resonance imaging contrast agent with tumor targeting and biomedical application thereof. The contrast agent can be specifically combined with a transferrin receptor 1 with high expression on the surface of tumor cells, consists of genetic engineering recombinant protein and gadolinium chelate, and has a higher longitudinal relaxation rate than a commercial contrast agent maguey (Gd-DTPA). The invention provides the contrast of the imaging effect of the animal tumor model carried out by the magnevist, and indicates that the contrast agent can realize tumor specific identification and longer-time magnetic resonance imaging under lower injection dosage without repeated injection. The contrast agent can be intravenously administered, and is applied to early diagnosis of cancer, further identification of tumor metastasis and diagnosis of postoperative suspected relapse. |
| priorityDate | 2020-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.